Defunct Company
Total Trials
24
As Lead Sponsor
21
As Collaborator
3
Total Enrollment
1,902
NCT00658970
Evaluation of KX2-391 in Patients With Advanced Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2007
Completion: May 31, 2011
NCT01074138
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
Phase: Phase 2
Start: Feb 28, 2010
Completion: Oct 31, 2012
NCT02250157
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Start: Sep 5, 2014
Completion: Mar 4, 2020
NCT02326441
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Start: Dec 31, 2014
Completion: May 23, 2018
NCT02337205
Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
Completion: Mar 31, 2016
NCT04035473
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Start: Aug 1, 2015
Completion: Mar 27, 2019
NCT04180384
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Start: Sep 23, 2015
Completion: Jun 15, 2021
NCT02594371
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
Phase: Phase 3
Start: Dec 2, 2015
Completion: Jun 30, 2022
NCT02730481
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Start: Mar 31, 2016
Completion: May 31, 2021
NCT02838628
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Role: Collaborator
Start: Apr 11, 2016
Completion: Dec 22, 2017
NCT02970539
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Start: Dec 8, 2016
Completion: Dec 31, 2022
NCT02963168
A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Start: Apr 20, 2017
Completion: Apr 30, 2020
NCT03285490
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Start: Sep 15, 2017
Completion: Apr 24, 2019
NCT03285477
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Start: Sep 18, 2017
NCT04168957
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Start: Oct 25, 2017
Completion: Nov 12, 2020
NCT03987685
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Start: Jul 19, 2018
Completion: Jan 9, 2021
NCT03575780
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
Start: Sep 7, 2018
Completion: Oct 10, 2019
NCT03588039
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Start: Oct 25, 2018
Completion: May 12, 2023
NCT03544567
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Start: Dec 21, 2018
NCT04993040
A PK Study of Oraxol in Breast Cancer Patients
Start: Apr 22, 2019
Completion: Dec 9, 2020
NCT03892018
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Start: Aug 5, 2019
NCT04136834
A Phase I Open-label Study for Subjects With Advanced Malignancies
Start: Apr 21, 2021
Completion: Dec 1, 2022
NCT04878484
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Start: Aug 11, 2021
Completion: Dec 31, 2024
NCT05487651
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Start: Oct 1, 2022